Epigenetic therapy for solid tumors: from bench science to clinical trials
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Epigenetic therapy for solid tumors: from bench science to clinical trials
Authors
Keywords
-
Journal
Epigenomics
Volume 7, Issue 2, Pages 215-235
Publisher
Future Medicine Ltd
Online
2015-05-05
DOI
10.2217/epi.14.73
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer Cells Acquire Resistance to Anticancer Drugs: An Update
- (2016) Hsing-Pang Lu et al. Biomedical Journal
- 5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft
- (2015) Alexandra Borodovsky et al. Oncotarget
- Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.
- (2015) Sevin Turcan et al. Oncotarget
- Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers
- (2015) Huili Li et al. Oncotarget
- Interpreting the language of histone and DNA modifications
- (2014) Scott B. Rothbart et al. Biochimica et Biophysica Acta-Gene Regulatory Mechanisms
- A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer
- (2014) R M Glasspool et al. BRITISH JOURNAL OF CANCER
- Epigenetic Targeting of Ovarian Cancer Stem Cells
- (2014) Yinu Wang et al. CANCER RESEARCH
- Epigenetic targeting in pancreatic cancer
- (2014) Jasmijn G.M. van Kampen et al. CANCER TREATMENT REVIEWS
- Epigenetic Interventions Increase the Radiation Sensitivity of Cancer Cells
- (2014) Juan Ren et al. CURRENT PHARMACEUTICAL DESIGN
- SGI-110 and entinostat therapy reduces lung tumor burden and reprograms the epigenome
- (2014) Carmen S. Tellez et al. INTERNATIONAL JOURNAL OF CANCER
- Harnessing the potential of epigenetic therapy to target solid tumors
- (2014) Nita Ahuja et al. JOURNAL OF CLINICAL INVESTIGATION
- Vorinostat as a radiosensitizer for brain metastasis: a phase I clinical trial
- (2014) Wenyin Shi et al. JOURNAL OF NEURO-ONCOLOGY
- Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression
- (2014) Noemi Reguart et al. LUNG CANCER
- Cancer Epigenetics: Tumor Heterogeneity, Plasticity of Stem-like States, and Drug Resistance
- (2014) Hariharan Easwaran et al. MOLECULAR CELL
- Inhibition of HDAC1 and DNMT1 Modulate RGS10 Expression and Decrease Ovarian Cancer Chemoresistance
- (2014) Ercan Cacan et al. PLoS One
- Anticancer efficacy of cisplatin and trichostatin A or 5-aza-2′-deoxycytidine on ovarian cancer
- (2013) F Meng et al. BRITISH JOURNAL OF CANCER
- A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group
- (2013) P A Cassier et al. BRITISH JOURNAL OF CANCER
- Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies
- (2013) Gerald S. Falchook et al. INVESTIGATIONAL NEW DRUGS
- A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer
- (2013) I. Garrido-Laguna et al. INVESTIGATIONAL NEW DRUGS
- Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study
- (2013) Tien Hoang et al. INVESTIGATIONAL NEW DRUGS
- Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor
- (2013) Denise A. Yardley et al. JOURNAL OF CLINICAL ONCOLOGY
- The Making of I-BET762, a BET Bromodomain Inhibitor Now in Clinical Development
- (2013) Yujun Zhao et al. JOURNAL OF MEDICINAL CHEMISTRY
- Garcinol sensitizes human pancreatic adenocarcinoma cells to gemcitabine in association with microRNA signatures
- (2013) Mansi A. Parasramka et al. MOLECULAR NUTRITION & FOOD RESEARCH
- The future of epigenetic therapy in solid tumours—lessons from the past
- (2013) Nilofer Azad et al. Nature Reviews Clinical Oncology
- A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium
- (2013) Alexandra P. Zorzi et al. PEDIATRIC BLOOD & CANCER
- The novel HDAC inhibitor NDACI054 sensitizes human cancer cells to radiotherapy
- (2013) Stephanie Hehlgans et al. RADIOTHERAPY AND ONCOLOGY
- Gossypol and an HMT G9a inhibitor act in synergy to induce cell death in pancreatic cancer cells
- (2013) Y Yuan et al. Cell Death & Disease
- Epigenetic alteration and microRNA dysregulation in cancer
- (2013) Hiromu Suzuki et al. Frontiers in Genetics
- Targeting the Epigenome in Lung Cancer: Expanding Approaches to Epigenetic Therapy
- (2013) Marko Jakopovic et al. Frontiers in Oncology
- Transient Low Doses of DNA-Demethylating Agents Exert Durable Antitumor Effects on Hematological and Epithelial Tumor Cells
- (2012) Hsing-Chen Tsai et al. CANCER CELL
- Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas
- (2012) Mei Dong et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Immunomodulatory activity of SGI-110, a 5-aza-2′-deoxycytidine-containing demethylating dinucleotide
- (2012) Sandra Coral et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Epigenetic Resensitization to Platinum in Ovarian Cancer
- (2012) D. Matei et al. CANCER RESEARCH
- A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: A gynecologic oncology group study
- (2012) Don S. Dizon et al. GYNECOLOGIC ONCOLOGY
- Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma: A Multicenter Phase I/II Study With Biomarker and Pharmacokinetic Analysis of Tumors From Patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group
- (2012) Winnie Yeo et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Trial of Erlotinib With and Without Entinostat in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed on Prior Chemotherapy
- (2012) Samir E. Witta et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination of AT-101/cisplatin overcomes chemoresistance by inducing apoptosis and modulating epigenetics in human ovarian cancer cells
- (2012) Burcak Karaca et al. MOLECULAR BIOLOGY REPORTS
- Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer
- (2012) Missak Haigentz et al. ORAL ONCOLOGY
- Evaluation of Romidepsin for Clinical Activity and Radioactive Iodine Reuptake in Radioactive Iodine–Refractory Thyroid Carcinoma
- (2012) Eric J. Sherman et al. THYROID
- Phase I–II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo
- (2011) B. Ramaswamy et al. BREAST CANCER RESEARCH AND TREATMENT
- A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer
- (2011) P N Munster et al. BRITISH JOURNAL OF CANCER
- Combination Therapy with Vidaza and Entinostat Suppresses Tumor Growth and Reprograms the Epigenome in an Orthotopic Lung Cancer Model
- (2011) Steven A. Belinsky et al. CANCER RESEARCH
- Curcumin Analogue CDF Inhibits Pancreatic Tumor Growth by Switching on Suppressor microRNAs and Attenuating EZH2 Expression
- (2011) B. Bao et al. CANCER RESEARCH
- Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer
- (2011) Victoria L. Luchenko et al. CELL CYCLE
- Phase I Study of Decitabine in Combination with Vorinostat in Patients with Advanced Solid Tumors and Non-Hodgkin's Lymphomas
- (2011) Anastasios Stathis et al. CLINICAL CANCER RESEARCH
- Differential DNA Methylation Alterations in Radiation-Sensitive and -Resistant Cells
- (2011) M. Ahmad Chaudhry et al. DNA AND CELL BIOLOGY
- Epigenetics and chemoresistance in colorectal cancer: An opportunity for treatment tailoring and novel therapeutic strategies
- (2011) Francesco Crea et al. DRUG RESISTANCE UPDATES
- Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic
- (2011) Jacob E. Shabason et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Methylation of the promoter of human leukocyte antigen class I in human esophageal squamous cell carcinoma and its histopathological characteristics
- (2011) Sun Qifeng et al. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
- A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03
- (2011) Fabio M. Iwamoto et al. NEURO-ONCOLOGY
- Histone deacetylase inhibition decreases proliferation and potentiates the effect of ionizing radiation in atypical teratoid/rhabdoid tumor cells
- (2011) J. A. Knipstein et al. NEURO-ONCOLOGY
- Targeting the epigenome for treatment of cancer
- (2011) E-J Geutjes et al. ONCOGENE
- Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies
- (2011) A. J. Christiansen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Promises and challenges of anticancer drugs that target the epigenome
- (2011) Inge Verbrugge et al. Epigenomics
- Combination Epigenetic Therapy Has Efficacy in Patients with Refractory Advanced Non-Small Cell Lung Cancer
- (2011) R. A. Juergens et al. Cancer Discovery
- Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer
- (2010) Siqing Fu et al. CANCER
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
- (2010) Sreenath V. Sharma et al. CELL
- The Design of Phase II Clinical Trials Testing Cancer Therapeutics: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee
- (2010) L. Seymour et al. CLINICAL CANCER RESEARCH
- Preclinical evidence for a beneficial impact of valproate on the response of small cell lung cancer to first-line chemotherapy
- (2010) Roland Hubaux et al. EUROPEAN JOURNAL OF CANCER
- Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma
- (2010) Sean J. Whittaker et al. JOURNAL OF CLINICAL ONCOLOGY
- Vorinostat (NSC# 701852) in Patients with Relapsed Non-small Cell Lung Cancer: A Wisconsin Oncology Network Phase II Study
- (2010) Anne M. Traynor et al. Journal of Thoracic Oncology
- Phase II Study of the Histone Deacetylase Inhibitor Romidepsin in Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30304)
- (2010) Gregory A. Otterson et al. Journal of Thoracic Oncology
- S110, a 5-Aza-2'-Deoxycytidine-Containing Dinucleotide, Is an Effective DNA Methylation Inhibitor In vivo and Can Reduce Tumor Growth
- (2010) J. C. Chuang et al. MOLECULAR CANCER THERAPEUTICS
- As we bring demethylating drugs to the clinic, we better know the DICE being cast
- (2010) P M Lizardi ONCOGENE
- Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors
- (2010) Lisa A Cowan et al. Epigenomics
- Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)
- (2009) L. R. Molife et al. ANNALS OF ONCOLOGY
- Considerations for the Use of Imaging Tools for Phase II Treatment Trials in Oncology
- (2009) L. K. Shankar et al. CLINICAL CANCER RESEARCH
- Alternate Endpoints for Screening Phase II Studies
- (2009) N. Dhani et al. CLINICAL CANCER RESEARCH
- Curcumin as an Anti-Cancer Agent: Review of the Gap Between Basic and Clinical Applications
- (2009) G. Bar-Sela et al. CURRENT MEDICINAL CHEMISTRY
- Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study
- (2009) Evanthia Galanis et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma
- (2009) Richard L. Piekarz et al. JOURNAL OF CLINICAL ONCOLOGY
- Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non–Small-Cell Lung Cancer
- (2009) Suresh S. Ramalingam et al. JOURNAL OF CLINICAL ONCOLOGY
- Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance
- (2009) R. Humeniuk et al. MOLECULAR CANCER THERAPEUTICS
- DNA methylation protects hematopoietic stem cell multipotency from myeloerythroid restriction
- (2009) Ann-Marie Bröske et al. NATURE GENETICS
- Hypermethylation of HLA class I gene is associated with HLA class I down-regulation in human gastric cancer
- (2009) Q. Ye et al. TISSUE ANTIGENS
- Hydralazine inhibits human cervical cancer cell growth in vitro in association with APC demethylation and re-expression
- (2008) Yinhong Song et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Clinical and Molecular Responses in Lung Cancer Patients Receiving Romidepsin
- (2008) D. S. Schrump et al. CLINICAL CANCER RESEARCH
- Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors
- (2008) J. S. de Bono et al. CLINICAL CANCER RESEARCH
- A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) in Metastatic Breast Cancer: A California Cancer Consortium Study
- (2008) T. H. Luu et al. CLINICAL CANCER RESEARCH
- Most mammalian mRNAs are conserved targets of microRNAs
- (2008) R. C. Friedman et al. GENOME RESEARCH
- A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study
- (2008) Susan C. Modesitt et al. GYNECOLOGIC ONCOLOGY
- Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine
- (2008) Carlo Stresemann et al. INTERNATIONAL JOURNAL OF CANCER
- Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)
- (2008) Robert P. Whitehead et al. INVESTIGATIONAL NEW DRUGS
- Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer
- (2008) Johan Vansteenkiste et al. INVESTIGATIONAL NEW DRUGS
- ERα negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor
- (2008) Jiang Fan et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Cancer testis antigens in human melanoma stem cells: Expression, distribution, and methylation status
- (2008) Luca Sigalotti et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Lack of Therapeutic Effect of the Histone Deacetylase Inhibitor Vorinostat in Patients with Metastatic Radioiodine-Refractory Thyroid Carcinoma
- (2008) Jennifer A. Woyach et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Epigenetic interplay between histone modifications and DNA methylation in gene silencing
- (2008) T VAISSIERE et al. MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More